



## PTC Therapeutics to Participate at Upcoming Investor Conferences

May 2, 2024

WARREN, N.J., May 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:

**RBC Capital Markets 2024 Global Healthcare Conference**  
Tuesday, May 14, at 11:00 am EDT

**Bank of America Securities 2024 Health Care Conference**  
Thursday, May 16, at 11:40 am EDT / 08:40 am PDT

The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at <https://ir.ptcbio.com/events-presentations> and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

### **About PTC Therapeutics, Inc.**

PTC is a global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at [www.ptcbio.com](http://www.ptcbio.com) and follow us on Instagram, Facebook, Twitter, and LinkedIn.

### **For More Information:**

#### **Investors:**

Kylie O'Keefe  
+1 (908) 300-0691  
[kokeefe@ptcbio.com](mailto:kokeefe@ptcbio.com)

#### **Media:**

Jeanine Clemente  
+1 (908) 912-9406  
[jclemente@ptcbio.com](mailto:jclemente@ptcbio.com)

 View original content: <https://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-302133727.html>

SOURCE PTC Therapeutics, Inc.